Handelsavisen
prelaunch
Companies Healthcare EKSO.O
EK
EKSO.O NASDAQ Advanced Medical Equipment & Technology

Ekso Bionics Holdings Inc

$12,01
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
42,8M USD
P/E
EV / Rev
4,2x
Div yield
Op margin
-47,2 %
ROE
-20,0 %
Net margin
-48,8 %
Debt / equity
0,46
Beta
52w range
Volume
Day range
Prev close
$12,01
Open
Next earnings
Ex-dividend
TR 1Y
About

Ekso Bionics Holdings Inc develops and commercializes wearable bionic exoskeletons for medical rehabilitation and industrial applications, generating revenue through product sales and service contracts.

Business. Ekso Bionics Holdings Inc (EKSO.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, generating revenue primarily through product sales. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
1 buy1 hold0 sell
Avg 12m price target9,50

Analyst recommendations

2 analysts · consensus Buy
Buy1
Hold1
Sell0
12-month price target
9,50
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-20,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EKSO.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EKSO.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ekso Bionics Holdings Inc (EKSO.O) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, generating revenue primarily through product sales. Headquartered in the United States, the company is listed on the NASDAQ stock exchange. Specific operating segments and geographic revenue breakdowns are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Ekso Bionics operates with a market capitalization of $42.8 million and a price-to-book ratio of 3.55, indicating a premium valuation relative to its equity base. The company's liquidity position is characterized by a current ratio of 2.42, suggesting moderate short-term solvency, but its operating cash flow of -$6.1 million and free cash flow of -$2.0 million highlight ongoing cash burn. The debt-to-equity ratio of 0.46 reflects a conservative capital structure, with long-term debt of $5.6 million against total equity of $12.1 million.

    Profitability metrics reveal significant challenges, with a net loss of $2.4 million and an operating loss of $2.3 million in the latest period. Return on equity of -20.03% and return on assets of -8.95% underscore the company's inability to generate returns for shareholders or asset holders. Gross profit of $2.6 million on $4.95 million in revenue suggests margin pressures, with a gross margin of 53.3%, which is below the industry median for advanced medical equipment firms.

    The company's revenue is concentrated in a single business segment focused on exoskeletons for medical and industrial use, with no disclosed geographic diversification. This concentration increases exposure to market-specific risks, particularly in the healthcare and industrial sectors where adoption of bionic technology is still nascent.

    Looking ahead, Ekso Bionics is projected to face continued revenue and margin pressures, with no clear path to profitability in the near term. The company's operating cash flow and free cash flow remain negative, and its capital expenditures of -$8,000 suggest minimal investment in growth infrastructure. Analysts have assigned a mean price target of $9.50, which is below the current market price of $12.01, indicating a bearish outlook.

    Risk factors include liquidity constraints, with net cash negative after subtracting total debt, and a high probability of continued operating losses. The company's dilution risk is currently low, but its equity base is small, and any future capital raise could significantly dilute existing shareholders. No recent filings or transcripts indicate material changes in strategy or operations.

    Key takeaways
    • Ekso Bionics is valued at a premium to book despite significant operating losses and negative cash flows.
    • The company's gross margin of 53.3% is below the industry median for advanced medical equipment firms.
    • Revenue is concentrated in a single product line with no geographic diversification.
    • Analysts have assigned a bearish price target of $9.50, below the current market price of $12.01.
    • Liquidity constraints and negative operating cash flow pose ongoing risks to the company's financial stability.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew at a 3.3% CAGR over four years, indicating modest top-line expansion despite recent volatility.

    Cash conversion of 2.54 ranks best-in-class among 205 peers, suggesting superior operational efficiency relative to competitors.

    Capex to revenue ratio of -0.0016 sits in the top quartile, implying minimal capital intensity requirements.

    Long-term debt decreased to $4.1 million in FY2026, reflecting a gradual reduction in leverage obligations.

    Gross profit reached $9.5 million in FY2025, demonstrating the ability to generate positive gross margins on sales.

    BEAR CASE · 2

    The company carries a high credit risk flag, suggesting significant concerns regarding its ability to meet financial obligations.

    Free cash flow remained deeply negative at -$11.0 million in FY2026, highlighting persistent cash burn issues.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-04-28
    Q1 2026 · Quarter highlights

    Revenue $2.1M, −36,6% YoY; Net income −138,2% YoY.

    Revenue$2.1M−36,6 % YoY
    Operating income
    Net income-$6.9M−138,2 % YoY
    Free cash flow
    EPS
    Operating cash flow-$2.1M−8,0 % YoY
    Financials
    Income statement
    Revenue$2.1M
    Gross profit
    Operating income
    Net income-$6.9M
    Margins
    Gross margin
    Operating margin
    Net margin-321.6%
    FCF margin
    Balance sheet
    Total assets
    Total liabilities$13.9M
    Total equity$2.1M
    Cash & equivalents
    Long-term debt$3.8M
    Cash flow
    Operating cash flow-$2.1M
    CapEx$0.00
    Free cash flow
    SBC
    Highlights
    • Revenue $2.1M, −36,6% YoY
    • Net income −138,2% YoY
    • Net margin -321.6%

    Valuation TTM

    Market price
    $12,01
    Market cap
    $42.8M
    Enterprise value
    $48.4M
    P/E
    Non-GAAP P/E
    EV / Revenue
    4.2x
    EV / Op income
    EV / OCF
    P / B
    3.5x
    P / Tangible book
    3.5x
    Tangible book
    $12.1M
    Net cash
    -$5.6M
    Current ratio
    2.4
    Debt / equity
    0.5
    ROA
    -8.9%
    ROE
    -20.0%
    Cash conversion
    254.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,41
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,41
    Revenueno estimateno estimate22,7M USD
    Operating incomeno estimateno estimate-4,0M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target$9,50 · Median $9,50
    Low $9,50High $9,50
    Operating income · consensus-4,0M USD
    EPS surprise
    −1 097,6 %
    reported vs consensus · miss
    Revenue surprise
    −43,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$9,50
    Mean$9,50
    Median$9,50
    High$9,50
    Spot$12,01
    −20.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-47,2 %Below median
    Net Margin-48,8 %Below median
    ROE-20,0 %Below median
    Capex / Rev-0,2 %Above P75
    D/E0,46Bottom quartile
    Cash Conv2,54Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Ekso Bionics Holdings Inc Market data — financials · 2026-05-27
    • Ekso Bionics Holdings Inc Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Insider activity

    — missing data

    Short positioning

    180.5Kshares short-16.1% vs prior
    4.92days to cover
    1.1Kfails-to-deliver
    as of 2026-04-30 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EKSO.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-04-28 19:18 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 2.1M · Net USD -6.9M
    2026-02-23 16:08 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 3.1M · Net USD -4.7M
    2026-02-23 16:08 UTCEARNINGSAnnual results — FY 2026 Revenue USD 12.8M · Net USD -11.7M
    2025-10-28 16:05 UTCEARNINGSQuarterly results — Q3 2025 Revenue USD 4.2M · Net USD -1.4M
    2025-07-28 16:11 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 2.1M · Net USD -2.7M
    2025-05-05 16:05 UTCEARNINGSQuarterly results — Q1 2025 Revenue USD 3.4M · Net USD -2.9M
    2025-03-03 16:05 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 5.1M · Net USD -3.4M
    2025-03-03 16:05 UTCEARNINGSAnnual results — FY 2025 Revenue USD 17.9M · Net USD -11.3M
    2024-10-28 16:08 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 4.1M · Net USD -2.1M
    2024-07-29 16:05 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 5.0M · Net USD -2.4M
    2024-03-04 16:05 UTCEARNINGSAnnual results — FY 2024 Revenue USD 18.3M · Net USD -15.2M
    2023-03-28 16:26 UTCEARNINGSAnnual results — FY 2023 Revenue USD 12.9M · Net USD -15.1M
    2022-02-24 16:05 UTCEARNINGSAnnual results — FY 2022 Revenue USD 11.2M · Net USD -9.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage